Market Overview

Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares

Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares
OncoSec Sees A Wider Loss Than Expected In Q4 While ImmunoPulse Trial Remains On Track
Earnings Scheduled For October 13, 2016

Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain.

Related Link: Galencia's Bid For Relypsa Is "Reasonable," Another Bidder "Unlikely"

According to the analysts, several near-term value drivers could constitute meaningful upside to their estimates. "We currently only model sales of ImmunoPulseā„¢ IL-12 in melanoma, without factoring in contributions from other potential therapeutic candidates generated by OncoSec's proprietary technology platform or possible applications in other indications, such as triple-negative breast cancer (TNBC)," the analysts wrote.

They also mentioned three major risks to their valuation, including (1) negative trial data, (2) failure to show synergy with approved immunotherapy drugs, (3) regulatory delays or rejections.

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email with the story link to let us know!

Latest Ratings for ONCS

Jul 2016Rodman & RenshawAssumesBuy
Mar 2016H.C. WainwrightMaintainsBuy
Jun 2015H.C. WainwrightAssumesBuy

View More Analyst Ratings for ONCS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (ONCS)

View Comments and Join the Discussion!